Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu

Abstract

The conditional expression of activated HER2/neu gene under its endogenous promoter in the mammary epithelium of the mouse results in accelerated lobular development and focal mammary tumors. Carcinogenesis, however, requires amplification and considerably increased expression levels of oncogenic neu. Deducing from the multiple genetic aberrations required for human breast cancer to develop, we hypothesized that in addition to the over-expression of an activated HER2/neu, secondary aberrations would occur. We have therefore conducted a genomic screen for chromosomal imbalances and translocations using comparative genomic hybridization and spectral karyotyping. The results reveal a moderate degree of chromosomal instability and micronuclei formation in short-term cultures established from primary tumors. Genomic instability appears to be linked to the amplification of functional centrosomes, a phenomenon that we frequently observed in other tumor types. Seventy per cent of the tumors revealed genomic amplification of HER2/neu, often in the form of double minute chromosomes, which correlated with recurring loss of mouse chromosome 4D-E, a region that is orthologous to distal human chromosome 1p. It is likely that this region contains putative tumor suppressor genes whose inactivation is required for tumor formation in this model of human breast cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Alitalo K, Saksela K, Winqvist R, Alitalo R, Keski-Oja J, Laiho M, Ilvonen M, Knuutila S, de la Chapelle A . 1985 Lancet 2: 1035–1039

  • Amundadottir LT, Johnson MD, Merlino G, Smith GH, Dickson RB . 1995 Cell Growth Differ. 6: 737–748

  • Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD, Muller WJ . 2000 Proc. Natl. Acad. Sci. USA 97: 3444–3449

  • Bieche I, Champeme MH, Lidereau R . 1994 Cancer Res. 54: 4274–4276

  • Carnero A, Hudson JD, Price CM, Beach DH . 2000 Nat. Cell Biol. 2: 148–155

  • Chen X, Zheng Y, Zhu J, Jiang J, Wang J . 2001 Oncogene 20: 769–774

  • Davisson MT . 1994 Gene 147: 157–160

  • Garini Y, Macville M, du Manoir S, Buckwald RA, Lavi M, Katzir N, Wine D, Bar-Am I, Schröck E, Cabib D, Ried T . 1996 Bioimaging 4: 65–72

  • Ghadimi BM, Sackett DL, Difilippantonio MJ, Schröck E, Neumann T, Jauho A, Auer G, Ried T . 2000 Genes Chrom. Cancer 27: 183–190

  • Ghadimi BM, Schröck E, Walker RL, Wangsa D, Jauho A, Meltzer PS, Ried T . 1999 Am. J. Pathol. 154: 525–536

  • Heim S, Mitelman F . 1995 Cancer Cytogenetics Wiley-Liss

    Google Scholar 

  • Hennighausen L. (ed) . 2000 Oncogene (Rev.) 19: 966–967

  • Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK, Waldman FM . 1995 Am. J. Pathol. 147: 905–911

  • Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D . 1992 Science 258: 818–821

  • Kellogg DR, Moritz M, Alberts BM . 1994 Annu. Rev. Biochem. 63: 639–674

  • Liu ML, Von Lintig FC, Liyanage M, Shibata MA, Jorcyk CL, Ried T, Boss GR, Green JE . 1998 Oncogene 17: 2403–2411

  • Liyanage M, Coleman A, du Manoir S, Veldman T, McCormack S, Dickson RB, Barlow C, Wynshaw-Boris A, Janz S, Wienberg J, Ferguson-Smith MA, Schröck E, Ried T . 1996 Nat. Genet. 14: 312–315

  • McCormack SJ, Weaver Z, Deming S, Natarajan G, Torri J, Johnson MD, Liyanage M, Ried T, Dickson RB . 1998 Oncogene 16: 2755–2766

  • Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P . 1988 Cell 54: 105–115

  • Müller WU, Nusse M, Miller BM, Slavotinek A, Viaggi S, Streffer C . 1996 Mutat. Res. 366: 163–169

  • O'Brien SJ, Menotti-Raymond M, Murphy WJ, Nash WG, Wienberg J, Stanyon R, Copeland NG, Jenkins NA, Womack JE, Marshall Graves JA . 1999 Science 286: 458–462 479–481

  • Revillion F, Bonneterre J, Peyrat JP . 1998 Eur. J. Cancer 34: 791–808

  • Ried T, Just KE, Holtgreve-Grez H, du Manoir S, Speicher MR, Schröck E, Latham C, Blegen H, Zetterberg A, Cremer T, Aver G . 1995 Cancer Res. 55: 5415–5423

  • Ried T, Knutzen R, Steinbeck R, Blegen H, Schröck E, Heselmeyer K, du Manoir S, Auer G . 1996 Genes Chrom. Cancer 15: 234–245

  • Ried T, Heselmeyer-Haddad K, Blegen H, Schröck E, Auer G . 1999 Genes Chrom. Cancer 25: 195–204

  • Schröck E, Badger P, Larson D, Erdos M, Wynshaw-Boris A, Ried T, Brody L . 1996a Hum. Genet. 97: 256–259

  • Schröck E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T . 1996b Science 273: 494–497

  • Stewart TA, Pattengale PK, Leder P . 1984 Cell 38: 627–637

  • Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP . 1998 Genes Chrom. Cancer 21: 177–184

  • Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV . 1994 Nature 369: 669–671

  • Weaver ZA, McCormack SJ, Liyanage M, du Manoir S, Coleman A, Schröck E, Dickson RB, Ried T . 1999 Genes Chrom. Cancer 25: 251–260

  • Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Henninghausen L, Wynshaw-Boris A, Deng CX . 1999a Nat. Genet. 22: 37–43

  • Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, Deng CX . 1999b Mol. Cell 3: 389–395

Download references

Acknowledgements

The authors would like to thank Michael J Difilippantonio, Kerstin Heselmeyer-Haddad, Joseph Cheng and Buddy Chen for critically reading and editing the manuscript. ER Andrechek was supported by the US Army Scholarship #DAMD17-99-1-9285.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thomas Ried.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montagna, C., Andrechek, E., Padilla-Nash, H. et al. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene 21, 890–898 (2002). https://doi.org/10.1038/sj.onc.1205146

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205146

Keywords

This article is cited by

Search

Quick links